Data Year:

For its 2025 fiscal year, SERES THERAPEUTICS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Eric D. Shaff
Former President and Chief Executive Officer
Total Compensation $1,775,549 View details Pay Rank By Title In Biotechnology industry #496 View more
Thomas J. DesRosier
Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer
Total Compensation $1,136,023 View details Pay Rank By Title In Biotechnology industry #151 View more
Matthew Henn Ph.D.
President and Chief Scientific Officer
Total Compensation $1,014,347 View details Pay Rank By Title In Biotechnology industry #157 View more
Teresa L. Young Ph.D.
Former Executive Vice President and Chief Commercial and Strategy Officer
Total Compensation $1,021,462 View details Pay Rank By Title In Biotechnology industry #156 View more
Marella Thorell
Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer
Total Compensation $1,113,396 View details Pay Rank By Title In Biotechnology industry #361 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at SERES THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SERES THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SERES THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Eric D. Shaff
Former President and Chief Executive Officer
Total Cash $408,333 Equity $1,338,870 Other $28,346 $1,775,549
Thomas J. DesRosier
Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer
Total Cash $679,567 Equity $446,290 Other $10,166 $1,136,023
Matthew Henn Ph.D.
President and Chief Scientific Officer
Total Cash $489,300 Equity $521,972 Other $3,075 $1,014,347
Teresa L. Young Ph.D.
Former Executive Vice President and Chief Commercial and Strategy Officer
Total Cash $489,300 Equity $521,972 Other $10,190 $1,021,462
Marella Thorell
Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer
Total Cash $661,067 Equity $446,290 Other $6,039 $1,113,396
For its 2023 fiscal year, SERES THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Claire M. Fraser, Ph.D. Total Cash $438,151
Dennis A. Ausiello, M.D. Total Cash $222,268
Grégory Behar Total Cash $196,726
Kurt C. Graves Total Cash $219,226
Meryl S. Zausner Total Cash $32,697
Paul R. Biondi Total Cash $211,726
Richard N. Kender Total Cash $232,692
Stephen A. Berenson Total Cash $249,226
Willard H. Dere, M.D. Total Cash $225,233
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.